ATAD2 and cancer: ATAD2 is overexpressed in multiple types of cancer including breast, lung, gastric, endometrial, colorectal, renal, and prostate [51,52,53,63,64,185,188,189,190], and overexpression of ATAD2 is often correlated with poor patient outcomes, and can be used as prognostic marker [51,52,53].